Which Endpoints Matter Most in Transthyretin Amyloid Cardiomyopathy Trials? Are We Comparing Apples to Apples?
Keeping Current CME
English - March 26, 2024 14:30 - 16 minutes - 16.2 MB - ★★★★ - 22 ratingsScience Health & Fitness Medicine Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Current Unmet Needs in Schizophrenia: Assessing Gaps in Care
Do you know how to interpret the results of recent phase 3 clinical trials in patients with transthyretin amyloid cardiomyopathy (ATTR-CM)?
Credit available for this activity expires: 3/22/25
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1000444?ecd=bdc_podcast_libsyn_mscpedu